Journal article 502 views 85 downloads
Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register
Neurology - Neuroimmunology Neuroinflammation, Volume: 9, Issue: 1, Start page: e1118
Swansea University Author: Rod Middleton
-
PDF | Version of Record
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Download (366.52KB)
DOI (Published version): 10.1212/nxi.0000000000001118
Abstract
To understand the course of recovery from coronavirus disease 2019 (COVID-19) among patients with multiple sclerosis (MS) and to determine its predictors, including patients' pre-COVID-19 physical and mental health status.<h4>Methods</h4>This prospective and longitudinal cohort stud...
Published in: | Neurology - Neuroimmunology Neuroinflammation |
---|---|
ISSN: | 2332-7812 2332-7812 |
Published: |
Ovid Technologies (Wolters Kluwer Health)
2022
|
Online Access: |
Check full text
|
URI: | https://cronfa.swan.ac.uk/Record/cronfa59132 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
first_indexed |
2022-01-10T15:30:05Z |
---|---|
last_indexed |
2022-01-19T04:28:58Z |
id |
cronfa59132 |
recordtype |
SURis |
fullrecord |
<?xml version="1.0"?><rfc1807><datestamp>2022-01-18T16:15:09.0610328</datestamp><bib-version>v2</bib-version><id>59132</id><entry>2022-01-10</entry><title>Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register</title><swanseaauthors><author><sid>005518f819ef1a2a13fdf438529bdfcd</sid><ORCID>0000-0002-2130-4420</ORCID><firstname>Rod</firstname><surname>Middleton</surname><name>Rod Middleton</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-01-10</date><deptcode>HDAT</deptcode><abstract>To understand the course of recovery from coronavirus disease 2019 (COVID-19) among patients with multiple sclerosis (MS) and to determine its predictors, including patients' pre-COVID-19 physical and mental health status.<h4>Methods</h4>This prospective and longitudinal cohort study recruited patients with MS who reported COVID-19 from March 17, 2020, to March 19, 2021, as part of the United Kingdom MS Register (UKMSR) COVID-19 study. Participants used online questionnaires to regularly update their COVID-19 symptoms, recovery status, and duration of symptoms for those who fully recovered. Questionnaires were date stamped for estimation of COVID-19 symptom duration for those who had not recovered at their last follow-up. The UKMSR holds demographic and up-to-date clinical data on participants as well as their web-based Expanded Disability Status Scale (web-EDSS) and Hospital Anxiety and Depression Scale (HADS) scores. The association between these factors and recovery from COVID-19 was assessed using multivariable Cox regression analysis.<h4>Results</h4>Of the 7,977 patients with MS who participated in the UKMSR COVID-19 study, 599 reported COVID-19 and prospectively updated their recovery status. Twenty-eight hospitalized participants were excluded. At least 165 participants (29.7%) had long-standing COVID-19 symptoms for ≥4 weeks and 69 (12.4%) for ≥12 weeks. Participants with pre-COVID-19 web-EDSS scores ≥7, participants with probable anxiety and/or depression (HADS scores ≥11) before COVID-19 onset, and women were less likely to report recovery from COVID-19.<h4>Discussion</h4>Patients with MS are affected by postacute sequelae of COVID-19. Preexisting severe neurologic impairment or mental health problems appear to increase this risk. These findings can have implications in tailoring their post-COVID-19 rehabilitation.</abstract><type>Journal Article</type><journal>Neurology - Neuroimmunology Neuroinflammation</journal><volume>9</volume><journalNumber>1</journalNumber><paginationStart>e1118</paginationStart><paginationEnd/><publisher>Ovid Technologies (Wolters Kluwer Health)</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>2332-7812</issnPrint><issnElectronic>2332-7812</issnElectronic><keywords/><publishedDay>1</publishedDay><publishedMonth>1</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-01-01</publishedDate><doi>10.1212/nxi.0000000000001118</doi><url/><notes/><college>COLLEGE NANME</college><department>Health Data Science</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>HDAT</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>Multiple Sclerosis Society Grant: 131</funders><lastEdited>2022-01-18T16:15:09.0610328</lastEdited><Created>2022-01-10T15:27:02.3624568</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Afagh</firstname><surname>Garjani</surname><order>1</order></author><author><firstname>Rod</firstname><surname>Middleton</surname><orcid>0000-0002-2130-4420</orcid><order>2</order></author><author><firstname>Richard</firstname><surname>Nicholas</surname><order>3</order></author><author><firstname>Nikos</firstname><surname>Evangelou</surname><order>4</order></author></authors><documents><document><filename>59132__22097__b6423119082342529266004d4b7e6a59.pdf</filename><originalFilename>59132.pdf</originalFilename><uploaded>2022-01-10T15:29:10.6066441</uploaded><type>Output</type><contentLength>375319</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc-nd/4.0/</licence></document></documents><OutputDurs/></rfc1807> |
spelling |
2022-01-18T16:15:09.0610328 v2 59132 2022-01-10 Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register 005518f819ef1a2a13fdf438529bdfcd 0000-0002-2130-4420 Rod Middleton Rod Middleton true false 2022-01-10 HDAT To understand the course of recovery from coronavirus disease 2019 (COVID-19) among patients with multiple sclerosis (MS) and to determine its predictors, including patients' pre-COVID-19 physical and mental health status.<h4>Methods</h4>This prospective and longitudinal cohort study recruited patients with MS who reported COVID-19 from March 17, 2020, to March 19, 2021, as part of the United Kingdom MS Register (UKMSR) COVID-19 study. Participants used online questionnaires to regularly update their COVID-19 symptoms, recovery status, and duration of symptoms for those who fully recovered. Questionnaires were date stamped for estimation of COVID-19 symptom duration for those who had not recovered at their last follow-up. The UKMSR holds demographic and up-to-date clinical data on participants as well as their web-based Expanded Disability Status Scale (web-EDSS) and Hospital Anxiety and Depression Scale (HADS) scores. The association between these factors and recovery from COVID-19 was assessed using multivariable Cox regression analysis.<h4>Results</h4>Of the 7,977 patients with MS who participated in the UKMSR COVID-19 study, 599 reported COVID-19 and prospectively updated their recovery status. Twenty-eight hospitalized participants were excluded. At least 165 participants (29.7%) had long-standing COVID-19 symptoms for ≥4 weeks and 69 (12.4%) for ≥12 weeks. Participants with pre-COVID-19 web-EDSS scores ≥7, participants with probable anxiety and/or depression (HADS scores ≥11) before COVID-19 onset, and women were less likely to report recovery from COVID-19.<h4>Discussion</h4>Patients with MS are affected by postacute sequelae of COVID-19. Preexisting severe neurologic impairment or mental health problems appear to increase this risk. These findings can have implications in tailoring their post-COVID-19 rehabilitation. Journal Article Neurology - Neuroimmunology Neuroinflammation 9 1 e1118 Ovid Technologies (Wolters Kluwer Health) 2332-7812 2332-7812 1 1 2022 2022-01-01 10.1212/nxi.0000000000001118 COLLEGE NANME Health Data Science COLLEGE CODE HDAT Swansea University Multiple Sclerosis Society Grant: 131 2022-01-18T16:15:09.0610328 2022-01-10T15:27:02.3624568 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Afagh Garjani 1 Rod Middleton 0000-0002-2130-4420 2 Richard Nicholas 3 Nikos Evangelou 4 59132__22097__b6423119082342529266004d4b7e6a59.pdf 59132.pdf 2022-01-10T15:29:10.6066441 Output 375319 application/pdf Version of Record true This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. true eng http://creativecommons.org/licenses/by-nc-nd/4.0/ |
title |
Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register |
spellingShingle |
Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register Rod Middleton |
title_short |
Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register |
title_full |
Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register |
title_fullStr |
Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register |
title_full_unstemmed |
Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register |
title_sort |
Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register |
author_id_str_mv |
005518f819ef1a2a13fdf438529bdfcd |
author_id_fullname_str_mv |
005518f819ef1a2a13fdf438529bdfcd_***_Rod Middleton |
author |
Rod Middleton |
author2 |
Afagh Garjani Rod Middleton Richard Nicholas Nikos Evangelou |
format |
Journal article |
container_title |
Neurology - Neuroimmunology Neuroinflammation |
container_volume |
9 |
container_issue |
1 |
container_start_page |
e1118 |
publishDate |
2022 |
institution |
Swansea University |
issn |
2332-7812 2332-7812 |
doi_str_mv |
10.1212/nxi.0000000000001118 |
publisher |
Ovid Technologies (Wolters Kluwer Health) |
college_str |
Faculty of Medicine, Health and Life Sciences |
hierarchytype |
|
hierarchy_top_id |
facultyofmedicinehealthandlifesciences |
hierarchy_top_title |
Faculty of Medicine, Health and Life Sciences |
hierarchy_parent_id |
facultyofmedicinehealthandlifesciences |
hierarchy_parent_title |
Faculty of Medicine, Health and Life Sciences |
department_str |
Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine |
document_store_str |
1 |
active_str |
0 |
description |
To understand the course of recovery from coronavirus disease 2019 (COVID-19) among patients with multiple sclerosis (MS) and to determine its predictors, including patients' pre-COVID-19 physical and mental health status.<h4>Methods</h4>This prospective and longitudinal cohort study recruited patients with MS who reported COVID-19 from March 17, 2020, to March 19, 2021, as part of the United Kingdom MS Register (UKMSR) COVID-19 study. Participants used online questionnaires to regularly update their COVID-19 symptoms, recovery status, and duration of symptoms for those who fully recovered. Questionnaires were date stamped for estimation of COVID-19 symptom duration for those who had not recovered at their last follow-up. The UKMSR holds demographic and up-to-date clinical data on participants as well as their web-based Expanded Disability Status Scale (web-EDSS) and Hospital Anxiety and Depression Scale (HADS) scores. The association between these factors and recovery from COVID-19 was assessed using multivariable Cox regression analysis.<h4>Results</h4>Of the 7,977 patients with MS who participated in the UKMSR COVID-19 study, 599 reported COVID-19 and prospectively updated their recovery status. Twenty-eight hospitalized participants were excluded. At least 165 participants (29.7%) had long-standing COVID-19 symptoms for ≥4 weeks and 69 (12.4%) for ≥12 weeks. Participants with pre-COVID-19 web-EDSS scores ≥7, participants with probable anxiety and/or depression (HADS scores ≥11) before COVID-19 onset, and women were less likely to report recovery from COVID-19.<h4>Discussion</h4>Patients with MS are affected by postacute sequelae of COVID-19. Preexisting severe neurologic impairment or mental health problems appear to increase this risk. These findings can have implications in tailoring their post-COVID-19 rehabilitation. |
published_date |
2022-01-01T04:16:12Z |
_version_ |
1763754086031687680 |
score |
11.017776 |